{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:30:48Z","timestamp":1765279848582},"reference-count":40,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.ygyno.2014.03.574","type":"journal-article","created":{"date-parts":[[2014,4,5]],"date-time":"2014-04-05T18:31:07Z","timestamp":1396722667000},"page":"467-472","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance"],"prefix":"10.1016","volume":"133","author":[{"given":"Pauline","family":"Wimberger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issam","family":"Chebouti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Kasimir-Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Lachmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eberhard","family":"Kuhlisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Kimmig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erg\u00fcn","family":"S\u00fcleyman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Dominik","family":"Kuhlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2014.03.574_bb0005","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0959-8049(96)00492-3","article-title":"Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990","volume":"33","author":"Black","year":"1997","journal-title":"Eur J Cancer"},{"issue":"Suppl. 8","key":"10.1016\/j.ygyno.2014.03.574_bb0205","doi-asserted-by":"crossref","first-page":"viii7","DOI":"10.1093\/annonc\/mdi961","article-title":"2004 Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)","volume":"16","author":"du Bois","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0015","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0020","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1245\/s10434-010-0964-9","article-title":"Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group)","volume":"17","author":"Wimberger","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0025","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1634\/theoncologist.4-2-87","article-title":"Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy","volume":"4","author":"Bookman","year":"1999","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0030","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/j.seminoncol.2008.12.003","article-title":"Management of recurrent ovarian carcinoma: current status and future directions","volume":"36","author":"Martin","year":"2009","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0035","first-page":"5721","article-title":"Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model","volume":"9","author":"Byrne","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0040","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nrc909","article-title":"VEGF and the quest for tumour angiogenesis factors","volume":"2","author":"Ferrara","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0045","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ctrv.2011.11.009","article-title":"Biomarkers in the development of anti-angiogenic therapies for ovarian cancer","volume":"38","author":"Raja","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0050","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrc2403","article-title":"VEGF-targeted therapy: mechanisms of anti-tumour activity","volume":"8","author":"Ellis","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0055","first-page":"3193","article-title":"Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer","volume":"8","author":"Cooper","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0060","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.clinbiochem.2004.01.014","article-title":"Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients","volume":"37","author":"Kassim","year":"2004","journal-title":"Clin Biochem"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0065","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0070","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0210","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.18_suppl.lba5503","volume":"31","author":"du Bois","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0080","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0215","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.18_suppl.lba5002","article-title":"AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)","volume":"30","author":"Pujade-Lauraine","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0090","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/(SICI)1097-0142(19970701)80:1<98::AID-CNCR13>3.0.CO;2-A","article-title":"Vascular endothelial growth factor expression in early stage ovarian carcinoma","volume":"80","author":"Paley","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0095","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/bjc.1997.537","article-title":"Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels","volume":"76","author":"Yamamoto","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0100","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1002\/cncr.23024","article-title":"Zone-specific remodeling of tumor blood vessels affects tumor growth","volume":"110","author":"Tilki","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0105","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1097-2765(00)80426-8","article-title":"CEA-related cell adhesion molecule 1: a potent angiogenic factor and a major effector of vascular endothelial growth factor","volume":"5","author":"Ergun","year":"2000","journal-title":"Mol Cell"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0110","first-page":"125","article-title":"Methods to evaluate the formation and stabilization of blood vessels and their role in tumor growth and metastasis","volume":"58","author":"Kilic","year":"2001","journal-title":"Methods Mol Med"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0115","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/cncr.22076","article-title":"A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation","volume":"107","author":"Fehm","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0220","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/0032472031000141283","article-title":"Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. Establishment of objective criteria for the evaluation of immunostained cells","volume":"1","author":"Borgen","year":"1999","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0125","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1158\/1078-0432.CCR-09-2797","article-title":"Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers","volume":"16","author":"Smith","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0130","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1021\/bi8000352","article-title":"VEGF-A165 induces human aortic smooth muscle cell migration by activating neuropilin-1-VEGFR1-PI3K axis","volume":"47","author":"Banerjee","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0135","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1084\/jem.20091846","article-title":"Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma","volume":"207","author":"Helfrich","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0140","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00418-011-0898-8","article-title":"Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab","volume":"137","author":"Weisshardt","year":"2012","journal-title":"Histochem Cell Biol"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0145","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/ijc.24028","article-title":"Functional significance of VEGFR-2 on ovarian cancer cells","volume":"124","author":"Spannuth","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0150","doi-asserted-by":"crossref","first-page":"a006676","DOI":"10.1101\/cshperspect.a006676","article-title":"The role of the tumor microenvironment in regulating angiogenesis","volume":"2","author":"Watnick","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0155","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ijc.23963","article-title":"Autocrine VEGF-A\/KDR loop protects epithelial ovarian carcinoma cells from anoikis","volume":"124","author":"Sher","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0160","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrclinonc.2009.63","article-title":"Biomarkers of response and resistance to antiangiogenic therapy","volume":"6","author":"Jain","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0165","first-page":"31","article-title":"Clinical significance of VEGFR-2 and VEGFR-3 expression in ovarian cancer patients","volume":"62","author":"Klasa-Mazurkiewicz","year":"2011","journal-title":"Pol J Pathol"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0170","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/IGC.0b013e318216cb91","article-title":"Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy","volume":"21","author":"Aktas","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0175","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1200\/JCO.2001.19.2.368","article-title":"Occult tumor cells in bone marrow of patients with locoregionally restricted ovarian cancer predict early distant metastatic relapse","volume":"19","author":"Braun","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0180","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/IGC.0b013e3182907109","article-title":"Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancer","volume":"23","author":"Fehm","year":"2013","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0185","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/cncr.20449","article-title":"Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma","volume":"101","author":"Nishida","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0190","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1083\/jcb.200709114","article-title":"The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching","volume":"181","author":"Kappas","year":"2008","journal-title":"J Cell Biol"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0195","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cell.2009.12.046","article-title":"Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development","volume":"140","author":"Lichtenberger","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2014.03.574_bb0200","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/cncr.21145","article-title":"Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines","volume":"104","author":"Wey","year":"2005","journal-title":"Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814008166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814008166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T10:03:40Z","timestamp":1597658620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825814008166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0090825814008166"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.03.574","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.03.574","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}